ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,343Medicare Part D Prescriptions Filled, Including Refills

Rank: 64 out of 1269

$564K Total Retail Price of All Prescriptions

Rank: 112 out of 1269

309 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 309 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

8% of this provider’s 309 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 9,277 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LEVOTHYROXINE SODIUM 394 367 1 4
SIMVASTATIN 379 346 2 3
LISINOPRIL 315 296 3 1
METOPROLOL TARTRATE 299 266 4 6
TRAMADOL HCL 270 252 5 16
FUROSEMIDE 258 249 6 5
OMEPRAZOLE 257 226 7 8
HYDROCHLOROTHIAZIDE 239 195 8 10
METOPROLOL SUCCINATE 202 178 9 13
GABAPENTIN 197 171 10 17
AMLODIPINE BESYLATE 196 162 11 2
POLYETHYLENE GLYCOL 3350 187 186 12 50
METFORMIN HCL 185 154 13 9
LANTUS 170 144 14 39
RANITIDINE HCL 164 153 15 27
DONEPEZIL HCL 162 144 16 22
ATENOLOL 156 142 17 14
RISPERIDONE 143 120 18 43
CITALOPRAM HBR 131 118 19 21
ALBUTEROL SULFATE 130 127 20 88
TRAZODONE HCL 124 124 21 36
ALENDRONATE SODIUM 123 118 22 28
POTASSIUM CHLORIDE 118 118 23 26
MIRTAZAPINE 105 105 24 24
ATORVASTATIN CALCIUM 104 94 25 7
NOVOLOG 104 104 25 82
LOSARTAN POTASSIUM 96 96 27 15
IPRATROPIUM-ALBUTEROL 91 90 28 86
LISINOPRIL-HYDROCHLOROTHIAZIDE 90 80 29 33
TAMSULOSIN HCL 87 87 30 31
NAMENDA 86 86 31 38
HYDROCODONE-ACETAMINOPHEN 86 69 S3 31 20
SERTRALINE HCL 77 74 33 23
NITROGLYCERIN PATCH 75 75 34 114
QUETIAPINE FUMARATE 72 72 35 53
ESCITALOPRAM OXALATE 70 61 36 58
LACTULOSE 70 70 36 67
PREDNISONE 66 65 38 45
DIVALPROEX SODIUM 65 48 39 54
BACLOFEN 65 42 39 103
ENULOSE 64 64 41 286
CLOPIDOGREL 64 64 41 32
CYMBALTA 61 49 43 70
SYNTHROID 61 47 43 72
TRIAMCINOLONE ACETONIDE 59 40 45 131
LYRICA 56 47 46 92
SPIRIVA 53 50 47 64
JANTOVEN 52 52 48 52
ALLOPURINOL 51 50 49 49
LEVEMIR 50 48 50 201
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 5, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.